EMA Recommends Approval for Pancreatic Cancer Drug
The European Medicines Agency has backed the authorization of Rasonque for adult patients with metastatic pancreatic cancer.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Should medical regulators prioritize faster drug approval processes even if it means shorter evaluation periods?
The European Medicines Agency (EMA) has recommended marketing authorization for the oral drug Rasonque to treat adults with metastatic pancreatic adenocarcinoma. The medication targets patients who have received at least one prior therapy.
Why it matters
Rasonque addresses a significant unmet medical need for patients who face a poor prognosis and limited treatment alternatives. The drug was identified as a high-priority medicine under the Cancer Medicines Pathfinder project.
In a phase 3 study of 500 patients, Rasonque showed a median progression-free survival of 7.2 months, compared to 3.6 months with chemotherapy. Approximately 92 percent of study participants carried a confirmed RAS G12 mutation.
The players
European Medicines Agency
This is the decentralized agency of the European Union responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
European Commission
This is the executive branch of the European Union that makes final decisions on marketing authorizations for medicines based on EMA recommendations.
The details
Rasonque, which contains the active substance daraxonrasib, works by binding to cyclophilin A to form a complex that attaches to and blocks RAS proteins. Regulators utilized a phased review approach, evaluating data as it was submitted rather than waiting for a single application, which reduced the assessment time to under 150 days.
Timeline
The phased review of Rasonque data began in early July 2026.
The EMA issued its recommendation for marketing authorization on October 15, 2026.
Health Landscape
The drug's prioritization through the Cancer Medicines Pathfinder project highlights how the initiative accelerates access to therapies that solve specific clinical needs. This regulatory milestone follows the broader industry trend of adopting phased reviews to shorten approval timelines for critical oncology treatments.
Patients with metastatic pancreatic adenocarcinoma may soon have a new oral treatment option following their first round of therapy. While the EMA has provided a favorable recommendation, actual patient access and insurance coverage will depend on subsequent pricing and reimbursement decisions in each individual member state.
The takeaway
Rasonque demonstrates significant improvement in survival outcomes for patients with metastatic pancreatic adenocarcinoma compared to standard chemotherapy. Patients should consult with their oncologists to determine if this new therapy is appropriate for their specific medical history and mutation profile.
Further reading
Learn more about ongoing developments in oncology treatments by visiting the Cancer section.
Source note: This article includes information reported by European Medicines Agency (EMA).
Live Poll
Should medical regulators prioritize faster drug approval processes even if it means shorter evaluation periods?
